Myriad Genetics shares retreat on Court decision Investors initially pushed the stock up by focusing on the bright side of the ruling. The Supreme Court said Myriad does have the legal right to patent forms of human’s genetic code that can be predictive of who might contract breast or ovarian cancer, says Michael Bennett, professor of law at Northeastern University. Investors may […]